Raptor Pharmaceutical Brief Report by IEW Research and Issued by BrokerBank Securities, Inc.

NEW YORK, April 9, 2015 /PRNewswire/ -- Raptor Pharmaceutical Corp. RPTP a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs include RP103 that is used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company's other clinical-stage product candidates comprise Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical product candidates include cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

On 2nd April 2015, shares of the firm rose 5.61% to $10.54 on Thursday after the company priced an underwritten public offering of common stock.

On 30th March 2015, the company announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of common stock sold in the offering at the public offering price, less the underwriting discounts and commissions.

For further details, please read our full report at:

http://bit.ly/-RPTP-AnalystBriefReport

Copy and paste to browser may be required.

This report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this report have not been compensated in any form.  A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Stella Nguyen, CFA Candidate. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/raptor-pharmaceutical-brief-report-by-iew-research-and-issued-by-brokerbank-securities-inc-300063012.html

SOURCE BrokerBank Securities, Inc.